CEFMATILEN HYDROCHLORIDE MONOHYDRATE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H14N8O5S4.ClH.H2O
Molecular Weight	569.058
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure of CEFMATILEN HYDROCHLORIDE MONOHYDRATE

Structure Search

SMILES

O.Cl.NC1=NC(=CS1)C(=N\O)\C(=O)N[C@H]2[C@H]3SCC(SCSC4=CNN=N4)=C(N3C2=O)C(O)=O

InChI

InChIKey=LBWIJMWZWJRRMO-AWXOXGPMSA-N

InChI=1S/C15H14N8O5S4.ClH.H2O/c16-15-18-5(2-30-15)8(21-28)11(24)19-9-12(25)23-10(14(26)27)6(3-29-13(9)23)31-4-32-7-1-17-22-20-7;;/h1-2,9,13,28H,3-4H2,(H2,16,18)(H,19,24)(H,26,27)(H,17,20,22);1H;1H2/b21-8-;;/t9-,13-;;/m1../s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11400319
Curator's Comment: description was created based on several sources, including http://google.com/patents/EP0467647B1 | https://www.ncbi.nlm.nih.gov/pubmed/11400306 | https://www.ncbi.nlm.nih.gov/pubmed/8585742 | https://www.ncbi.nlm.nih.gov/pubmed/9612604

Cefmatilen (codenamed S-1090) is an orally-active cephalosporin antibiotic, that shows high activity against a variety of Gram-positive and Gram-negative bacteria, including Streptococcus pyogenes and Neisseria gonorrhoeae.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: https://ncim-stage.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI%20Metathesaurus&code=C0964022	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Bacterial infections 235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17983256	Curative		Phase III 665	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
2.79 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.78 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.01 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.58 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.1 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
4.25 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
6.1 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.98 μg/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

AUC

Value	Dose	Analyte	Population
20.35 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
25.51 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
11.37 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
15.06 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
19.25 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
27.52 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
39.53 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
24.89 μg × h/mL CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
3.23 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.77 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.89 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.99 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	75 mg single, oral dose: 75 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.84 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
3.08 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.08 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED
2.53 h CLINICAL TRIAL https://pubmed.ncbi.nlm.nih.gov/29681381/	200 mg 2 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	CEFMATILEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED

F_unbound

Value	Dose	Co-administered	Analyte	Population
2.7% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29681381/			CEFMATILEN plasma	Homo sapiens

Doses

Dose	Population	Adverse events
400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/	Other AEs: ALT increased... Other AEs: ALT increased (33%) Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/
400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/	Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/

AEs

AE	Significance	Dose	Population
ALT increased	33%	400 mg 2 times / day multiple, oral Highest studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/29681381/

PubMed

Title	Date	PubMed
[Toxicity study of cefmatilen hydrochloride hydrate (S-1090) (5)--Six-month repeated oral dose toxicity study and supplement study in rats].	2001-05	11400319

Patents

Sample Use Guides

In Vivo Use Guide

200 mg 2 x/day for 8 days

Route of Administration: Oral

In Vitro Use Guide

The bactericidal activities of S-1090 and the other agents at four times the MIC for Escherichia coli ATCC 25922 were determined. An overnight culture in Mueller-Hinton broth was inoculated into fresh broth, and the mixture was incubated, with constant shaking, until the viability reached 2 3 10^6 to 3 3 10^6 CFU/ml. After the addition of antibiotics, the cultures were incubated at 358C and the number of viable cells was determined.

Name

Type

Language

CEFMATILEN HYDROCHLORIDE HYDRATE

Preferred Name

English

CEFMATILEN HYDROCHLORIDE MONOHYDRATE

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2-AMINO-4-THIAZOLYL)(HYDROXYIMINO)ACETYL)AMINO)-8-OXO-3-(((1H-1,2,3-TRIAZOL-4-YLTHIO)METHYL)THIO)-, MONOHYDROCHLORIDE, MONOHYDRATE, (6R-(6.ALPHA.,7.BETA.(Z)))-

Common Name

English

CEFMATILEN MONOHYDROCHLORIDE MONOHYDRATE

Common Name

English

CEFMATILEN HYDROCHLORIDE HYDRATE [JAN]

Common Name

English

(-)-CEFMATILEN MONOHYDROCHLORIDE MONOHYDRATE

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2Z)-(2-AMINO-4-THIAZOLYL)(HYDROXYIMINO)ACETYL)AMINO)-8-OXO-3-(((1H-1,2,3-TRIAZOL-4-YLTHIO)METHYL)THIO)-, MONOHYDROCHLORIDE, MONOHYDRATE, (6R,7R)-

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2Z)-2-(2-AMINO-4-THIAZOLYL)-2-(HYDROXYIMINO)ACETYL)AMINO)-8-OXO-3-(((1H-1,2,3-TRIAZOL-5-YLTHIO)METHYL)THIO)-, HYDROCHLORIDE, HYDRATE (1:1:1), (6R,7R)-

Common Name

English

Code System Code Type Description

CAS

154776-45-1

Created by admin on Mon Mar 31 21:29:40 GMT 2025 , Edited by admin on Mon Mar 31 21:29:40 GMT 2025

PRIMARY

FDA UNII

PA4O9CKP1M

Created by admin on Mon Mar 31 21:29:40 GMT 2025 , Edited by admin on Mon Mar 31 21:29:40 GMT 2025

PRIMARY

PUBCHEM

9690121

Created by admin on Mon Mar 31 21:29:40 GMT 2025 , Edited by admin on Mon Mar 31 21:29:40 GMT 2025

PRIMARY

ACTIVE MOIETY


					T750UM24H8

CEFMATILEN

SUBSTANCE RECORD


					PA4O9CKP1M

CEFMATILEN HYDROCHLORIDE MONOHYDRATE

Details

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Approved Use

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound